Unknown

Dataset Information

0

Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.


ABSTRACT: Representative clinical case. A 74-year-old male patient was diagnosed with stage 3 mantle cell lymphoma in 2012. Because he was ineligible for intensive treatment (age, previous myocardial infarction [MI]), he received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemoimmunotherapy for 6 cycles (reaching complete response) and then rituximab maintenance (RM) for 2 years. One year after the end of RM, he relapsed with disseminated disease. He was started on ibrutinib 560 mg/day. Two weeks after the start of ibrutinib, he developed grade 3 diarrhea that required interruption of ibrutinib. Two weeks after the regular dose was restarted (month 3), the patient had repeated bleeding (patient was receiving aspirin for previous MI) and had to stop ibrutinib again. Because the patient was in partial response (PR) with lack of disease-associated symptoms, he was restarted on ibrutinib 280 mg/day with no further adverse events, and he had maintained PR at last follow-up (month 9 on ibrutinib).

SUBMITTER: Ruella M 

PROVIDER: S-EPMC6142482 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Walking a tightrope: clinical use of ibrutinib in mantle cell lymphoma in the elderly.

Ruella Marco M   Soubeyran Pierre P  

Hematology. American Society of Hematology. Education Program 20161201 1


Representative clinical case. A 74-year-old male patient was diagnosed with stage 3 mantle cell lymphoma in 2012. Because he was ineligible for intensive treatment (age, previous myocardial infarction [MI]), he received rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemoimmunotherapy for 6 cycles (reaching complete response) and then rituximab maintenance (RM) for 2 years. One year after the end of RM, he relapsed with disseminated disease. He was started on  ...[more]

Similar Datasets

| S-EPMC6580678 | biostudies-literature
2021-04-26 | GSE141336 | GEO
| PRJNA593190 | ENA
2021-04-26 | GSE141335 | GEO
| S-EPMC8057695 | biostudies-literature
| S-EPMC6853811 | biostudies-literature
2021-04-26 | GSE141334 | GEO
2021-04-26 | GSE141333 | GEO
| PRJNA593340 | ENA
| S-EPMC4513941 | biostudies-literature